Open Orphan plc(OPORF)
USD --+0.00%
Reward76High
Risk36Moderate
📊75%Data
2.3% dividend yield · Revenue down 32% YoY
OPORF
+0.0 · +0.00%
USD · PINK
Open Orphan plc | Healthcare
Quality Compounder
Market Cap:59.17M
ℹ️
Reward Rating
76
High
Top 10% (model universe)
75% data coverage
ℹ️
Risk Rating
36
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on OPORF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Open Orphan plc?

hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America.

OPORF · Verdict

Strong reward · moderate risk

OPORF stands out on valuation and balance sheet, but watch the volatility signal.

Based on 88% data coverage

OPORF · Verdict

What’s working & what to watch

Strengths 5

  • Valuation93/100

    P/E 12.1×

  • Balance sheet93/100

    Interest covered 14.9×

  • Profitability84/100

    17% net margin · 13% ROE

  • Growth81/100

    Revenue +19.4% CAGR

  • Cash flow69/100

    13% free-cash-flow margin

Watchouts 1

  • Volatility35/100

    Below average

Model-based scoring. For information only — not financial advice.

What is Open Orphan plc?

hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including assay development, cell based assays, molecular, immunology, virology, clinical field trail logistics, and biomarker analysis services. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 59.17M, and a P/E ratio of 8.6x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Strong margins and consistent earnings support financial stability.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: High (76)

The scoring profile indicates a strong reward potential, driven primarily by valuation and profitability. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap59.17M
P/E Ratio8.61
Dividend Yield2.32%
52 Week High0.35
52 Week Low0.0861
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding687M
No. of Employees301
IndustryDiagnostics & Research
ExchangePINK
Beta1.487
CurrencyUSD